KR100870077B1 - Combination product for the treatment of weaning systemic consumable syndrome (PMS) - Google Patents

Abstract

The present invention relates to a combination composition for the treatment of post-weaning systemic consumer syndrome (PMWS), and more particularly, including a respiratory disease treatment agent, an anti-inflammatory agent and an antidote, including antibiotics that can prevent / treat the symptoms associated with the disease. It relates to a composite composition. Therefore, the combination according to the present invention can not only improve the weight loss, systemic weakness, respiratory failure, etc. of pigs showing symptoms of weaning syndrome, but also significantly reduce mortality.

PMWS, systemic consumer syndrome

Description

Pharmaceutical formulation in the treatment of PMWS}

 The present invention relates to a combination composition for treating weaning systemic consumer syndrome (PMWS), and more particularly, including a respiratory disease treatment agent, an anti-inflammatory agent and an antidote, including antibiotics that can prevent / treat symptoms associated with the disease. It relates to a composite composition.

Post-weaning multisystemic wasting syndrome (PMWS), a recent swine disease, is mainly associated with weight loss, systemic weakness, atrophy, respiratory failure, diarrhea and skin in 5 to 12 week old weaning piglets. It shows clinical symptoms such as pale or jaundice, and the mortality rate of infected pigs is about 5 to 50%, but once the infection is done, there is no commodity value due to growth delay due to severe contraction of infected pigs. 1: Korean Pig House Pig House].

Major Clinical Symptoms of PMWS in Korea Clinical symptoms Weight loss and systemic breakdown Dyspnea cough Pneumonia diarrhea unit(%) 85 71 65 65 29

Since the disease was first reported in Canada in 1989, it has been reported in many countries around the world, including Europe, the United States, France, Spain, and Asia, and it is difficult to treat once a vaccine has not been developed. Moreover, when pigs get this disease, the immune system is broken, causing secondary diseases such as respiratory disease and pneumonia. In other words, the cause of PMWS is swine circovirus type 2 (PCV2) is a pathogen, porcine respiratory syndrome virus (PRRS), swine parvovirus (PPV), swine influenza virus (SIV), pig heterovirus (PEV) It also appears in the form of secondary bacterial infections or multiple infections, such as viruses, Glacier's disease, Mycoplasma, Pleural pneumonia, Pasteurella pneumonia (see Table 2: Swine Association Pig House).

Combined Infection Rate of PCV-2 and Other Pathogens in PMWS-producing Pigs Infection Type Mono infection Double infection Triple infection Quadruple infection percentage(%) 11 43 40 6

However, the latest known measures of PMWS include gentamicin to reduce direct mortality by preventing secondary infections, although it is only possible to improve the environment and nutrition, to minimize stress on pigs, and to treat secondary infections, although the causative agent is impossible. It is also widely used antibiotic therapy such as sulfa drug, theramycin, amoxicillin [Ref. In addition, therapies such as microbial therapies and immunopotentiators have been used to prevent side effects from antibiotic abuse and to increase self-immunity [see: Korean Patent Registration No. 468522; Korea Patent Registration No. 478845].

However, all these methods were not effective enough to improve weight loss, respiratory failure, mortality, etc. according to PMWS, and there is still a need for improvement.

Accordingly, the inventors of the present invention have made diligent efforts to solve the above problems, and as a result, preparations containing antibiotics such as gentamicin, anti-inflammatory agents such as dexolone, respiratory disease treatment agents such as metherin, and antidotes such as nipotan, PMWS By administering the symptomatic pig, it was confirmed that not only the symptoms were improved but also the mortality was significantly improved.

After all, it is an object of the present invention to provide a combination composition for treating PMWS, including antibiotics, anti-inflammatory agents, therapeutic agents for respiratory diseases and antidotes.

In order to achieve the above object, the present invention relates to an antibiotic 100 in the total composition content; Anti-inflammatory agent 78 to 85 parts by weight; 17 to 24 parts by weight of a respiratory disease treatment agent and 0.8 to 1.3 parts by weight of an antidote, wherein the antibiotic is at least one member selected from the group consisting of gentamicin, sulfa, teramycin, amoxicillin, kanamycin, and the anti-inflammatory agent is dexolone, The disease treatment agent is metherin, and the antidote is nipotan, which provides a composite composition for treating weaning systemic consumption syndrome (PMWS).

delete

delete

delete

delete

In another aspect, the present invention provides a composition further comprises 8 to 14 parts by weight of the taurine or vitamin preparation in addition to the total composition content.

The present invention also provides a composition in which the composition is administered to weaned pigs as a 3cc to 4cc injection on a daily basis of 8Kg and the dose is increased by 1 to 1.5cc according to an increase in the weight of 1 Kg.

Hereinafter, a preferred embodiment of the present invention will be described in detail. First, in describing the present invention, detailed descriptions of related well-known functions or configurations are omitted in order not to obscure the subject matter of the present invention.

As used herein, the terms "about", "substantially", and the like, are used at, or in close proximity to, numerical values when manufacturing and material tolerances inherent in the meanings indicated are intended to aid the understanding of the invention. Accurate or absolute figures are used to assist in the prevention of unfair use by unscrupulous infringers.

Looking more specifically with respect to the present invention PMWS therapeutic combination composition as follows.

Firstly, the present invention relates to a composite composition for treating PMWS, comprising: 100 antibiotics in the total composition content; Anti-inflammatory agent 78 to 85 parts by weight; 17 to 24 parts by weight of a respiratory disease treatment agent and 0.8 to 1.3 parts by weight of an antidote.

In general, the cause of PMWS is swine circovirus type 2 (PCV-2), which is not caused by the pathogen or the virus alone, but also appears as a secondary bacterial infection or complex infection depending on the environment. Clinical symptoms include weight loss, general weakness, respiratory failure, diarrhea, pale skin or jaundice.

Thus, although the present invention is not a direct treatment for the causative virus, as described above, the anti-inflammatory agent, anti-inflammatory agent, respiratory disease treatment agent and antidote for preventing and treating secondary respiratory diseases or pneumonia, which is caused by a broken immune system, as described above. Include together. Here, the antibiotic is administered by calculating one or more selected from gentamicin, sulfa agent, theramycin, amoxicillin, kanamycin to 100 of the total composition content, these are not completely excreted in vitro after administration and eventually remain in the body of harmful microorganisms The use should be minimized because it causes the resistance, but the problem that the pharmacological effect cannot be obtained when it is out of the above range and the use of an excessive amount are not preferable because there is no difference in effect expression compared to the side effects.

In addition, as an anti-inflammatory agent, for example, dexrone can be administered, 78 to 85 parts by weight of the total composition is preferably in the range, as a respiratory disease treatment agent for improving the clinical symptoms, such as respiratory failure, for example, mete Lean may be administered and preferably comprises a range of 17 to 24 parts by weight of the total composition content. In addition, as an antidote, for example, nipotan may be administered, and a range of 0.8 to 1.3 parts by weight is preferable in the total composition content. These are also undesirable because there is no difference in the expression of effects when compared to the side effects when used in excess, and the pharmacological effect is lowered when used in too small amounts.

In addition, the present invention further comprises 8 to 14 parts by weight of the total composition of the taurine or vitamin preparation in order to fully supplement the nutrition of the pig, it is also preferable to include other selenium, zinc oxide, immunostimulants or magiczyme together. .

In addition, the present invention is prepared in a dosage form for administration to pigs in a conventional manner using the composition and content, wherein the preferred dosage form is oral or parenteral, but injection is most preferred. The formulations of the invention can also be administered orally as solutions or aqueous suspensions in aqueous ethanol. Suspensions or solutions for oral administration are typically at about the same concentrations used for injection. However, it may be desirable to use higher doses when the medicament is administered orally than when administered by injection.

When administering the composition of the present invention as described above, the typical dose rate will depend on the condition and exact nature of the pig. For example, the typical dosage for administration by injection is preferably 3 cc to 4 cc on an 8 kg basis per day, depending on the pig. It is also possible to increase the dose of 1 to 1.5 cc with an increase of 1 kg of body weight.

Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples, but the present invention is not limited thereto.

Example : Preparation of Composite Composition

As summarized in the following Table 3, a composite was prepared according to a conventional method with components and contents according to the present invention.

 Compound composition and content Furtherance Kanamycin Dexon Meterin Nipotan Vitamin A Content (cc) 5 4 One 0.05 0.5

Experimental Example and Comparative Experimental Examples 1 to 3: comparison of weight gain and mortality

  1. Weight gain comparison

A 200-day-old weaning pig selected from a farm in Pyeongtaek, Gyeonggi-do, where PMWS has occurred in the past 1 to 2 years, was selected for 200 heads of pig circovirus type 2 antibodies. Then, these were again administered to the combination-administered group (50: experimental example), the non-administered group (50: comparative example 1), sulfa-administered group (50: comparative example 2), gentamicin-administered group (50: comparative experiment). Example 3), and 4 weeks old weaning pigs were inoculated with pig circovirus type 2 and parvovirus to induce PMWS. Then, the compound of Example was injected into the experimental group as an injection, and an average of about 7 Kg weaning pig was administered 3 cc per day, and in Comparative Experiment 2 and Comparative Experiment 3, respectively, sulfa and gentamicin were administered in the same manner as in the above example. It was. In addition, the change in the weight of the pigs was measured while observing their symptom changes for 30 days at 5 days intervals, and the results are summarized in Table 4 below.

Weight gain comparison division Start of medication 5 days 10 days 15th 20 days 25 days 30 days Experimental Example (㎏) 6.9 8.5 10.4 12.5 14.7 17.2 20.0 Comparative Experimental Example 1 (㎏) 6.8 7.5 8.4 9.4 10.5 11.9 13.5 Comparative Experimental Example 2 (㎏) 7.0 7.8 9.1 10.9 13.0 15.2 17.5 Comparative Experiment Example 3 (㎏) 6.9 7.8 9.5 11.3 13.5 15.9 18.4

As a result, the experimental example administered with the combination according to the present invention showed an increase rate of about 48% due to the maximum weight increase of 6.5 kg after 30 days compared to the comparative example, and the average daily gain was 0.437 for the experimental example. ㎏ / 1 day, in the case of the comparative experiment 0.223㎏ / 1 day it was confirmed that there is a significant difference.

  2. Mortality comparison

The change of clinical symptoms and mortality were investigated during the experiment of the experimental and comparative experiments for weaning pigs, and the results are summarized in Table 5 below.

Mortality comparison division Death toll (% mortality) Cause of death (marisu) Experimental Example 1 (2%) PMWS (1) Comparative Experimental Example 1 15 (30%) PMWS (8) / PMWS + Glacer's Disease (4) / Glassler's Disease (2) / Pleural Pneumonia (1) Comparative Experimental Example 2 5 (10%) PMWS (3) / PMWS + Glasser Disease Bottle (2) Comparative Experiment 3 4 (8%) PMWS (2) / PMWS + Glasser Disease Bottle (2)

As a result, respiratory symptoms were observed in many subjects in the early stages of the experiment, and the results of the visual observation of the excrement showed some diarrhea symptoms up to 5 days after weaning, but soon improved. In the case of mortality, in Comparative Example 1, a total of 15 died and a mortality was 30%, in Comparative Experiment 2, a total of 5 died and a mortality was 10%, and in Comparative Experiment 3, a total of 4 died. While the mortality was 8%, the experimental example in which the combination drug of the present invention was administered showed that the same clinical symptoms were observed in the same farms, although one patient with worsening PMWS died and showed 2% mortality. It was found that mortality was significantly reduced in the case of dosing.

As described above, the present invention relates to a composite composition for treating weaning systemic consumer syndrome (PMWS). Therefore, the combination according to the present invention not only improves symptoms such as weight loss, systemic weakness, respiratory failure, etc. of pigs showing symptoms of weaning syndrome, but also significantly reduces mortality.

In addition, the composition according to the present invention has a significant effect of compensatory increase after syndrome improvement.

The present invention described above is not limited to the above-described embodiments, and various substitutions, modifications, and changes can be made without departing from the technical spirit of the present invention. It will be obvious to him.

Claims (7)

For antibiotic 100 in the total composition content; Anti-inflammatory agent 78 to 85 parts by weight; 17 to 24 parts by weight of a respiratory disease treatment agent and 0.8 to 1.3 parts by weight of an antidote, The antibiotic is at least one member selected from the group consisting of gentamicin, sulfa drug, teramycin, amoxicillin, kanamycin, The anti-inflammatory agent is dexolone, The respiratory disease treatment agent is metherin, Said antidote is nipotan, characterized in that the combined composition for weaning systemic consumer syndrome (PMWS) treatment. delete delete delete delete The method of claim 1, The composition is additionally a composite composition for treating weaning systemic syndrome syndrome (PMWS), characterized in that it further comprises 8 to 14 parts by weight of the taurine or vitamin preparation in the total composition content. Systemic consumption syndrome (PMWS) characterized in that the composition according to claim 1 or 6 is administered to weaning pigs as a 3cc to 4cc injection on a daily basis of 8Kg and the dose is increased to 1 to 1.5cc according to an increase in the weight of 1 Kg. Method of administration of the combination composition for treatment.